Research programme: CCR5 antagonists - Boehringer Ingelheim
Latest Information Update: 21 Oct 2016
At a glance
- Originator Boehringer Ingelheim
- Mechanism of Action CCR5 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 19 Oct 2016 Euroscreen is now called Ogeda